# Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

> **NCT02724878** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 65 (actual)

## Conditions studied

- Advanced Non-Clear Cell Kidney Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT02724878
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-15
- **Primary completion:** 2019-11-13
- **Final completion:** 2024-12-31
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2025-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02724878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02724878, "Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02724878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*